Immunocore Holdings plc 8-K

What Happened
Immunocore Holdings plc filed an 8-K on January 30, 2026, announcing that David Berman notified the company on January 27, 2026 that he will resign as Head of Research & Development, effective February 27, 2026. The filing states his departure is to pursue another opportunity and was not the result of any disagreement with the company.

Key Details

• Filing: Form 8-K filed January 30, 2026 (Item 5.02: Departure of Directors or Certain Officers).
• Resignation notice date: January 27, 2026; effective date: February 27, 2026.
• Executive: David Berman, Head of Research & Development.
• Company action: Immunocore will not seek a direct replacement and will streamline and leverage its existing R&D structure.

Why It Matters
This is a material executive change in Immunocore’s R&D leadership, which oversees the company’s research programs and development pipeline. The company’s plan to redistribute responsibilities rather than hire a direct replacement could affect reporting lines and program management during the transition. Investors should note the personnel change and the company’s stated organizational approach; the filing does not indicate any disagreement or operational dispute.